GLP-1 pills are coming, and they could revolutionize weight-loss
Sep 17, 2024 · Dushay cited hopes that pill versions of GLP-1 drugs could ease shortages, come at lower cost and enhance convenience. But she and other doctors also warn about the potential for misuse, a...
FDA Approves First Generic of Once-Daily GLP-1 Injection to …
FDA approved the first generic referencing Victoza (liraglutide injection) 18 mg/3 mL, a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic control in adults and ...
Generic GLP-1 drug: FDA approves version of liraglutide ... - NBC News
Dec 23, 2024 · Demand for the drug, a first generation GLP-1, has been falling with the loss of patent protection last year and as patients move to more effective and once-weekly treatments such as Novo...
GLP-1 RAs efficacious for weight loss in overweight, obesity …
3 days ago · Retatrutide (12 mg once weekly) resulted in weight loss of up to 22.1% after 48 weeks; other novel single and combination GLP-1 agents were also efficacious. Adverse events were frequent (80 to 97 ...
FDA Approves Generic GLP-1 Medicine For Diabetes Treatment - U.S. News ...
THURSDAY, Dec. 26, (2024 HealthDay News) -- The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a daily injectable GLP-1 medicine for ...
Beyond Ozempic: New GLP-1 drugs promise weight loss and …
Drug companies are racing to develop GLP-1 drugs following the blockbuster success of Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and Zepbound. Some of the experimental drugs may...
GLP-1 nonresponders: Up to 1 in 5 people don't lose weight | AP News
Nov 23, 2024 · In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15% to 22% of their body weight — up to 50 pounds or more in many cases. But roughly 10% to 15% of patients in those trials were “nonresponders” who lost less than 5% of …
FDA clarifies policies for compounders as national GLP-1 supply …
Oct 22, 2024 · The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved.
GLP-1 compounding is still in limbo. Will the FDA leave it for the …
Dec 11, 2024 · About 12% of American adults have taken a GLP-1 medication, according to a May poll from KFF Health. And compounded versions may account for upwards of 20% of all GLP-1 prescriptions, CNN reported. But when the FDA backed down, letting compound pharmacies resume, the industry was still awaiting final word. That decision could take a while.
Many people using GLP-1s for weight loss stop treatment too soon ... - CNN
May 21, 2024 · An analysis of health insurance claims released Tuesday found that most people using GLP-1 medications – about 58% – were on their treatment plan for less than 12 weeks, falling short of a key...
- Some results have been removed